FDA delays decision on Biohaven's rare disease drug filing, plans adcomm
Biohaven is giving investors whiplash. Forty-eight hours after saying its filing was on track, the biopharma revealed the FDA has delayed a decision on its rare disease candidate troriluzole and plans to hold an advisory committee to discuss the application.
Biohaven is giving investors whiplash. Forty-eight hours after saying its filing was on track, the biopharma revealed the FDA has delayed a decision on its rare disease candidate troriluzole and plans to hold an advisory committee to discuss the application.
